Compare
Corvus Pharmaceuticals, Inc. vs Spero Therapeutics, Inc. vs Context Therapeutics Inc. vs Cumberland Pharmaceuticals Inc
| Latest fiscal year | Corvus Pharmaceuticals, Inc. CRVS | Spero Therapeutics, Inc. SPRO | Context Therapeutics Inc. CNTX | Cumberland Pharmaceuticals Inc CPIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $66.80M | n/a | $44.52M |
| Revenue growth (YoY) | n/a | +39.2% | n/a | +17.6% |
| Gross margin | n/a | n/a | n/a | 85.0% (computed) |
| Operating margin | n/a | 9.5% | n/a | -6.3% |
| Net margin | n/a | 12.8% | n/a | -6.4% |
| Net income | -$15.28M | $8.57M | -$36.12M | -$2.84M |
| EPS (Diluted) | -$0.53 | $0.15 | -$0.38 | -$0.19 |
| Operating cash flow | -$32.80M | -$12.62M | -$26.39M | $4.93M |
| Free cash flow | -$32.97M | n/a | -$26.42M | $4.83M |
| Cash & equivalents | $4.58M | $40.27M | $66.00M | $11.44M |
| Total assets | $71.12M | $68.92M | $68.49M | $76.82M |
| Total liabilities | $9.91M | $9.90M | $8.02M | $52.28M |
| Shareholders' equity | $61.20M | $59.02M | $60.47M | $24.88M |
| Return on year-end equity | -25.0% | 14.5% | -59.7% | -11.4% |
| Shares outstanding | 74.70M | 56.41M | 91.88M | 14.96M |
Revenue, most recent five fiscal years
| Fiscal year | Corvus Pharmaceuticals, Inc. | Spero Therapeutics, Inc. | Context Therapeutics Inc. | Cumberland Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | n/a | $66.80M Ended 2025-12-31 | n/a | $44.52M Ended 2025-12-31 |
| 1 year earlier | n/a | $47.98M Ended 2024-12-31 | n/a | $37.87M Ended 2024-12-31 |
| 2 years earlier | n/a | $103.78M Ended 2023-12-31 | n/a | $39.55M Ended 2023-12-31 |
| 3 years earlier | n/a | $53.51M Ended 2022-12-31 | n/a | $42.01M Ended 2022-12-31 |
| 4 years earlier | n/a | $18.26M Ended 2021-12-31 | n/a | $35.05M Ended 2021-12-31 |